| Year |
Citation |
Score |
| 2024 |
Kucera CW, Chappell NP, Tian C, Richardson MT, Tarney CM, Hamilton CA, Chan JK, Kapp DS, Leath CA, Casablanca Y, Rojas C, Sitler CA, Wenzel L, Klopp A, Jones NL, et al. Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors. Gynecologic Oncology. 184: 224-235. PMID 38340648 DOI: 10.1016/j.ygyno.2024.02.005 |
0.35 |
|
| 2023 |
Reddy M, Tian C, Liao CI, Winkler S, Johnson CR, Kapp DS, Darcy K, Chan JK. Exploring U.S. Hispanic origin groups diagnosed with uterine cancer - Are there disparities? Gynecologic Oncology. 181: 118-124. PMID 38150836 DOI: 10.1016/j.ygyno.2023.12.015 |
0.302 |
|
| 2023 |
Chan JK, Tian C, Kesterson JP, Lin KY, Darcy K, Richardson MT, Kapp DS, Monk BJ, McNally L, Landrum L, Copeland L, Walker JL, Wenham RM, Phippen N, Spirtos NM, et al. Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study. Gynecologic Oncology. 181: 54-59. PMID 38134754 DOI: 10.1016/j.ygyno.2023.12.009 |
0.337 |
|
| 2022 |
Chan JK, Tian C, Kesterson JP, Richardson MT, Lin K, Tewari KS, Herzog T, Kapp DS, Monk BJ, Casablanca Y, Hanjani P, Wenham RM, Walker J, McNally L, Copeland LJ, et al. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. Gynecologic Oncology. PMID 36244828 DOI: 10.1016/j.ygyno.2022.09.028 |
0.352 |
|
| 2022 |
Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, Robertson S, Copeland LJ, Walker JL, Wenham RM, Casablanca Y, Spirtos NM, Tewari KS, Bell JG. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstetrics and Gynecology. PMID 34991145 DOI: 10.1097/AOG.0000000000004642 |
0.318 |
|
| 2021 |
Abel MK, Liao CI, Chan C, Lee D, Rohatgi A, Darcy KM, Tian C, Mann AK, Maxwell GL, Kapp DS, Chan JK. Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study. Gynecologic Oncology. PMID 33722415 DOI: 10.1016/j.ygyno.2021.02.037 |
0.362 |
|
| 2021 |
Eaglehouse YL, Darcy KM, Tian C, Casablanca Y, Shriver CD, Zhu K. Racial-Ethnic Comparison of Guideline-Adherent Gynecologic Cancer Care in an Equal-Access System. Obstetrics and Gynecology. PMID 33706355 DOI: 10.1097/AOG.0000000000004325 |
0.309 |
|
| 2020 |
Richardson MT, Mysona DP, Klein DA, Mann A, Liao CI, Diver EJ, Darcy KM, Tian C, She JX, Ghamande S, Van Le L, Kapp DS, Chan JK. Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit. Gynecologic Oncology. PMID 32828578 DOI: 10.1016/J.Ygyno.2020.07.011 |
0.47 |
|
| 2020 |
Abel MK, Chan JK, Chow S, Darcy K, Tian C, Kapp DS, Mann AK, Liao CI. Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 32753561 DOI: 10.1136/Ijgc-2020-001646 |
0.394 |
|
| 2020 |
Rojas C, Tian C, Powell MA, Chan JK, Bateman NW, Conrads TP, Rocconi RP, Jones NL, Shriver CD, Hamilton CA, Maxwell GL, Casablanca Y, Darcy KM. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. Gynecologic Oncology. PMID 32029291 DOI: 10.1016/J.Ygyno.2020.01.017 |
0.379 |
|
| 2019 |
Gaulin NB, Lesnock JL, Tian C, Osei-Bonsu K, Jacobs A, Richard SD, Krivak TC, Miller EM, Shriver CD, Casablanca Y, Maxwell GL, Darcy KM. Survival disparities in vulvar cancer patients in Commission on Cancer®-accredited facilities. Gynecologic Oncology. PMID 31954540 DOI: 10.1016/J.Ygyno.2019.11.025 |
0.496 |
|
| 2019 |
Vaz J, Tian C, Richardson MT, Chan JK, Mysona D, Rao UN, Powell MA, Shriver CD, Hamilton CA, Casablanca Y, Maxwell GL, Darcy KM. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities. Gynecologic Oncology. PMID 31954536 DOI: 10.1016/J.Ygyno.2019.12.008 |
0.383 |
|
| 2019 |
Tarney CM, Wang G, Bateman NW, Conrads KA, Zhou M, Hood BL, Loffredo J, Tian C, Darcy KM, Hamilton CA, Casablanca Y, Lokshin A, Conrads TP, Maxwell GL. Biomarker Panel for Early Detection of Endometrial Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. American Journal of Obstetrics and Gynecology. PMID 31279844 DOI: 10.1016/J.Ajog.2019.06.005 |
0.434 |
|
| 2019 |
Craig ER, Tarney C, Tian C, Casablanca Y, Darcy K. Impact of Histology on Racial Disparities in Epithelial Ovarian Cancer Patients [39R] Obstetrics & Gynecology. 133. DOI: 10.1097/01.Aog.0000559154.99245.34 |
0.422 |
|
| 2019 |
Xu C, Tian C, Wang G, Bijelic L, Bateman NW, Conrads TP, Hamilton CA, Casablanca Y, Maxwell GL, Darcy KM. Treatment and survival in elderly women with gynecologic cancer not inferior with Medicare versus private insurance: A National Cancer Database investigation Gynecologic Oncology. 154: 195-196. DOI: 10.1016/J.Ygyno.2019.04.453 |
0.477 |
|
| 2019 |
Jackson AM, Casablanca Y, Tian C, Bateman NW, Conrads TP, Darcy KM. Survival trends in gynecologic malignancies display modest progress and persistent challenges: An investigation of future opportunities Gynecologic Oncology. 154: 187. DOI: 10.1016/J.Ygyno.2019.04.434 |
0.353 |
|
| 2019 |
Gaulin NB, Lesnock JL, Tian C, Jacobs A, Richard SD, Krivak TC, Miller EM, Casablanca Y, Darcy KM. Survival in elderly patients with vulvar cancer: A National Cancer Database study Gynecologic Oncology. 154: 115-116. DOI: 10.1016/J.Ygyno.2019.04.277 |
0.507 |
|
| 2019 |
Rojas C, Tian C, Huang Y, Zhou K, Bateman NW, Conrads TP, Hamilton CA, Maxwell GL, Casablanca Y, Darcy KM. The contributory factors to racial disparity in survival varied in uterine versus ovarian carcinosarcoma: A National Cancer Database investigation Gynecologic Oncology. 154: 112. DOI: 10.1016/J.Ygyno.2019.04.269 |
0.485 |
|
| 2019 |
Presti CL, Tian C, Oliver KE, Bateman NW, Conrads TP, Hamilton CA, Casablanca Y, Maxwell GL, Darcy KM. Factors to explain racial disparity in survival for women with uterine cancer: Further investigations by histologic subtype Gynecologic Oncology. 154: 23-24. DOI: 10.1016/J.Ygyno.2019.04.058 |
0.446 |
|
| 2019 |
Rojas C, Chappell NP, Tian C, Hamilton CA, Maxwell GL, Casablanca Y, Darcy KM. Histology matters in developing a framework for explaining racial disparity in cervical cancer survival Gynecologic Oncology. 153. DOI: 10.1016/J.Ygyno.2019.03.114 |
0.451 |
|
| 2018 |
Dubil EA, Tian C, Wang G, Tarney CM, Bateman NW, Levine DA, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM. Racial disparities in molecular subtypes of endometrial cancer. Gynecologic Oncology. 149: 106-116. PMID 29605044 DOI: 10.1016/J.Ygyno.2017.12.009 |
0.482 |
|
| 2018 |
Phippen NT, Tian C, Huang Y, Bateman NW, Hamilton CA, Maxwell GL, Darcy KM. Risk stratification in serous ovarian cancer using a classifier based on 30 transcripts Gynecologic Oncology. 149: 187-188. DOI: 10.1016/J.Ygyno.2018.04.427 |
0.403 |
|
| 2018 |
Chan JK, Mann AK, Freeman AH, Liao CI, Delic L, Tian C, Darcy KM, Kapp DS. Disparities in the survival trends in epithelial ovarian cancer patients in the United States Gynecologic Oncology. 149: 142-143. DOI: 10.1016/J.Ygyno.2018.04.326 |
0.475 |
|
| 2017 |
Tarney CM, Tian C, Craig ER, Crothers BA, Chan JK, Gist GD, Bateman NW, Conrads TP, Hamilton CA, Larry Maxwell G, Darcy KM. Relative Effects of Age, Race, and Stage on Mortality in Gestational Choriocarcinoma. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 29232272 DOI: 10.1097/Igc.0000000000001156 |
0.328 |
|
| 2017 |
Tarney CM, Tian C, Wang G, Dubil EA, Bateman NW, Chan JK, Elshaikh MA, Cote ML, Schildkraut JM, Shriver CD, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM. Impact of age at diagnosis on racial disparities in endometrial cancer patients. Gynecologic Oncology. PMID 28800945 DOI: 10.1016/J.Ygyno.2017.07.145 |
0.425 |
|
| 2017 |
Bateman NW, Dubil EA, Wang G, Hood BL, Oliver JM, Litzi TA, Gist GD, Mitchell DA, Blanton B, Phippen NT, Tian C, Zahn CM, Cohn DE, Havrilesky LJ, Berchuck A, et al. Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. Cancer. PMID 28654152 DOI: 10.1002/Cncr.30813 |
0.416 |
|
| 2017 |
Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecologic Oncology. PMID 28456378 DOI: 10.1016/J.Ygyno.2017.04.012 |
0.356 |
|
| 2017 |
Penick ER, Mhawech-Fauceglia P, Bateman N, Conrads K, Litzi T, Tian C, Hamilton CA, Darcy K, Maxwell G, Conrads T. Abstract 2359: Inhibition of the ATR kinase enhances therapeutic efficacy of cisplatin in ATM low uterine carcinosarcoma cells Cancer Research. 77: 2359-2359. DOI: 10.1158/1538-7445.Am2017-2359 |
0.338 |
|
| 2017 |
Penick E, Tian C, Wang G, Maxwell G, Hamilton C, Darcy K. Surrogates of Progression-Free Survival in Endometrial Cancer Patients: An Evaluation of Tissue Composition [19J] Obstetrics & Gynecology. 129. DOI: 10.1097/01.Aog.0000514994.62058.Ff |
0.467 |
|
| 2017 |
Penick ER, Tian C, Wang G, Bateman NW, Mhawech-Fauceglia P, Gist G, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM. Surrogates of progression-free survival in endometrial cancer patients: An evaluation of necrosis and other measures of tissue composition Gynecologic Oncology. 145: 124-125. DOI: 10.1016/J.Ygyno.2017.03.290 |
0.457 |
|
| 2017 |
Huang Y, Dubil EA, Tian C, Chan JK, Krivak TC, Bateman NW, Conrads TP, Hamilton CA, Darcy KM, Maxwell GL. Racial and ethnic outcome differences in the top five women’s cancers: A harmonized Surveillance, Epidemiology, and End Results study for diagnoses from 2000-2014 Gynecologic Oncology. 145: 93-94. DOI: 10.1016/J.Ygyno.2017.03.219 |
0.395 |
|
| 2017 |
Hope ER, Miller CR, Tian C, Conrads TP, Risinger JI, Hamilton CA, Maxwell GL, Darcy KM. Mutations and transcript expression of maternal embryonic leucine zipper kinase in endometrial cancer patients Gynecologic Oncology. 145: 87-88. DOI: 10.1016/J.Ygyno.2017.03.205 |
0.359 |
|
| 2017 |
Penick ER, Tian C, Bateman NW, Oliver J, Mitchell D, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM. CTNNB1 predicts better progression-free survival in endometrioid endometrial cancer patients treated with chemotherapy Gynecologic Oncology. 145: 81. DOI: 10.1016/J.Ygyno.2017.03.191 |
0.507 |
|
| 2017 |
Maxwell GL, Wang G, Tian C, Bateman NW, Casablanca Y, Havrilesky LJ, Birrer MJ, Hamilton CA, Conrads TP, Darcy KM. MS7 a transcript-based diagnostic classifier for metastatic disease and worse progression-free survival in endometrioid endometrial cancer patients Gynecologic Oncology. 145: 12. DOI: 10.1016/J.Ygyno.2017.03.045 |
0.438 |
|
| 2017 |
Dubil EA, Tian C, Wang G, Bateman NW, Levine DA, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM. Racial differences in molecular subtypes between black and white patients with endometrial cancer Gynecologic Oncology. 145: 11-12. DOI: 10.1016/J.Ygyno.2017.03.044 |
0.399 |
|
| 2016 |
Li Q, Song W, Wang W, Yao S, Tian C, Cai X, Wang L. Suppression of epithelial-mesenchymal transition in hepatocellular carcinoma cells by Krüppel-like Factor 4. Oncotarget. PMID 27102441 DOI: 10.18632/Oncotarget.8831 |
0.357 |
|
| 2015 |
Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecologic Oncology. PMID 26037898 DOI: 10.1016/J.Ygyno.2015.05.038 |
0.367 |
|
| 2015 |
Tian C, Gabrin MJ, Brower SL, Sargent DJ. Comment on: 'evaluation of chemoresponse assays as predictive markers'. British Journal of Cancer. 112: 1977-8. PMID 25989277 DOI: 10.1038/Bjc.2015.156 |
0.38 |
|
| 2015 |
Lowery WJ, Stany MP, Phippen NT, Bunch KP, Oliver KE, Tian C, Maxwell GL, Darcy KM, Hamilton CA. Survival advantage of marriage in uterine cancer patients contrasts poor outcome for widows: a Surveillance, Epidemiology and End Results study. Gynecologic Oncology. 136: 328-35. PMID 25546111 DOI: 10.1016/J.Ygyno.2014.12.027 |
0.527 |
|
| 2014 |
Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. British Journal of Cancer. 111: 843-50. PMID 25003664 DOI: 10.1038/Bjc.2014.375 |
0.472 |
|
| 2014 |
Krivak TC, Lele S, Richard S, Secord AA, Leath CA, Brower SL, Tian C, Moore RG. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. American Journal of Obstetrics and Gynecology. 211: 68.e1-8. PMID 24530815 DOI: 10.1016/J.Ygyno.2013.07.076 |
0.481 |
|
| 2014 |
Lowery WJ, Stany MP, Phippen NT, Bunch KP, Tian C, Maxwell GL, Darcy KM, Hamilton CA. Diminished survival of separated, divorced, or widowed uterine cancer patients: A potential focus for survivorship programs Gynecologic Oncology. 133: 206. DOI: 10.1016/J.Ygyno.2014.03.547 |
0.442 |
|
| 2014 |
Byrd K, Maxwell G, Bshara W, Risinger J, Tian C, Omilian A, Odunsi K, Morrison C, Conrads T, Consortium W. Subcellular localization of AT-rich interactive domain1A protein expression is associated with survival in epithelial ovarian and peritoneal carcinoma Gynecologic Oncology. 133: 93-94. DOI: 10.1016/J.Ygyno.2014.03.249 |
0.341 |
|
| 2013 |
Tian CQ, Darcy KM, Krivak TC, Deloia JA, Armstrong D, Davis W, Zhao H, Moysich K, Ambrosone CB. Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Frontiers in Oncology. 3: 206. PMID 23964347 DOI: 10.3389/Fonc.2013.00206 |
0.581 |
|
| 2013 |
Rutherford T, Orr J, Grendys E, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecologic Oncology. 131: 362-7. PMID 23954900 DOI: 10.1016/j.ygyno.2013.08.009 |
0.329 |
|
| 2013 |
Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. British Journal of Cancer. 108: 1231-7. PMID 23462720 DOI: 10.1038/Bjc.2013.70 |
0.512 |
|
| 2012 |
Shen K, Song N, Kim Y, Tian C, Rice SD, Gabrin MJ, Symmans WF, Pusztai L, Lee JK. A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. Plos One. 7: e49529. PMID 23185353 DOI: 10.1371/Journal.Pone.0049529 |
0.433 |
|
| 2012 |
Shen K, Qi Y, Song N, Tian C, Rice SD, Gabrin MJ, Brower SL, Symmans WF, O'Shaughnessy JA, Holmes FA, Asmar L, Pusztai L. Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial. Bmc Medical Genomics. 5: 51. PMID 23158478 DOI: 10.1186/1755-8794-5-51 |
0.399 |
|
| 2012 |
Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecologic Oncology. 125: 421-6. PMID 22261301 DOI: 10.1016/J.Ygyno.2012.01.008 |
0.483 |
|
| 2012 |
Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, DeLoia JA. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecologic Oncology. 124: 575-81. PMID 22112610 DOI: 10.1016/J.Ygyno.2011.11.022 |
0.553 |
|
| 2012 |
Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 118: 3087-94. PMID 22072418 DOI: 10.1002/Cncr.26618 |
0.438 |
|
| 2012 |
Chan J, Alvarez-Secord A, Tillmanns T, Moore K, Bevis K, ElNaggar A, Perry L, McClung C, Tian C, Huh W. Outcomes of ovarian cancer patients after bevacizumab and chemotherapy in primary vs. recurrent setting – A multi-institutional study Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.236 |
0.484 |
|
| 2012 |
Ueda S, Alvarez-Secord A, Huh W, Tillmanns T, Moore K, Previs R, Perry L, Kiet T, Tian C, Chan J. Determining surrogate endpoints predictive of overall survival in patients treated with bevacizumab for advanced ovarian cancer — A multi-institutional study Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.188 |
0.513 |
|
| 2011 |
Song N, Rice SD, Gingrich D, Wang D, Tian C, Ding Z, Brower SL, Ervin P, Gabrin MJ, Shen K. Evaluation of the performance of breast cancer cell line-derived multigene predictors of chemotherapy response in multiple clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 64. PMID 27958138 DOI: 10.1200/Jco.2011.29.27_Suppl.64 |
0.436 |
|
| 2011 |
Krivak TC, Darcy KM, Tian C, Bookman M, Gallion H, Ambrosone CB, Deloia JA. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecologic Oncology. 122: 121-6. PMID 21496891 DOI: 10.1016/J.Ygyno.2011.03.027 |
0.6 |
|
| 2011 |
Shen K, Tang G, Kim C, Pogue-Geile K, Anderson S, Constantino J, Bear H, Song N, Tian C, Gabrin M, Zhang Y, Geyer C, Wolmark N. P1-06-15: A Genomic Predictor Developed from Breast Cancer Cell Lines Predicts Both Disease-Free Survival and Overall Survival in Breast Cancer Patients Treated with Doxorubicin and Cyclophosphamide: A Collaborative Project of the NSABP and Precision Therapeutics. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-06-15 |
0.324 |
|
| 2010 |
Moore KN, Tian C, McMeekin DS, Thigpen JT, Randall ME, Gallion HH. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer. 116: 5407-14. PMID 20737572 DOI: 10.1002/cncr.25480 |
0.404 |
|
| 2010 |
Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 117: 324-9. PMID 20185168 DOI: 10.1016/J.Ygyno.2010.01.040 |
0.366 |
|
| 2010 |
Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, Bell J. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecologic Oncology. 116: 301-6. PMID 19945740 DOI: 10.1016/j.ygyno.2009.10.073 |
0.388 |
|
| 2010 |
Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, Bell J. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 116: 307-11. PMID 19944452 DOI: 10.1016/j.ygyno.2009.10.074 |
0.396 |
|
| 2010 |
Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Risinger JI, Thigpen JT, Fleming GF, Gallion HH, Maxwell GL. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 116: 355-61. PMID 19924790 DOI: 10.1002/cncr.24769 |
0.368 |
|
| 2010 |
Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbridge EJ. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 116: 452-8. PMID 19913895 DOI: 10.1016/J.Ygyno.2009.10.062 |
0.374 |
|
| 2010 |
Song N, Rice S, Gingrich D, Wang D, Tian C, Ding Z, Brower S, Ervin P, Huang S, Gabrin M, Shen K. Abstract P3-08-02: Pharmacogenomic Predictors of Patient Response to Chemotherapy Derived from Breast Cancer Cell Lines Combining Knowledge-Based and Data-Driven Methods Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-08-02 |
0.416 |
|
| 2010 |
Shen K, Rice S, Gingrich D, Wang D, Tian C, Ding Z, Brower S, Ervin P, Huang S, Gabrin M, Song N. Abstract P2-09-10: Feasibility Assessment of Pharmacogenomic Predictors Developed from Breast Cancer Cell Lines To Predict Breast Cancer Patient Pathological Response in Neoadjuvant Chemotherapy: Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-09-10 |
0.448 |
|
| 2010 |
Chan J, Tian C, Yang K, Kesterson J, Kapp D, Monk B, Herzog T, Bell J. The pattern of CA-125 normalization during chemotherapy predicts for recurrence and survival in patients with high-risk early-stage ovarian cancer: A gynecologic oncology group study Gynecologic Oncology. 116: 596. DOI: 10.1016/J.Ygyno.2009.10.019 |
0.477 |
|
| 2009 |
Darcy KM, Tian C, Ambrosone CB, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, DeLoia JA. A Gynecologic Oncology Group study of associations between polymorphisms in ABC transporter genes (ABCB1, ABCC2, and ABCG2) and outcome in advanced stage epithelial ovarian cancer treated with platinum and taxane chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5567. PMID 27962559 DOI: 10.1200/Jco.2009.27.15_Suppl.5567 |
0.544 |
|
| 2009 |
Kunos C, Tian C, Waggoner S, Rose PG, Lanciano R. Retrospective analysis of concomitant Cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 19: 1258-63. PMID 19823064 DOI: 10.1111/Igc.0B013E3181B33Ace |
0.402 |
|
| 2009 |
Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstetrics and Gynecology. 114: 537-46. PMID 19701032 DOI: 10.1097/Aog.0B013E3181B12F99 |
0.368 |
|
| 2009 |
Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecologic Oncology. 115: 81-5. PMID 19596139 DOI: 10.1016/J.Ygyno.2009.06.021 |
0.436 |
|
| 2009 |
Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer. 115: 4210-7. PMID 19536873 DOI: 10.1002/cncr.24482 |
0.394 |
|
| 2009 |
Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, McGuire WP, Hanjani P, Warshal D, Greer BE, Belinson J, Birrer MJ. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecologic Oncology. 113: 341-7. PMID 19272639 DOI: 10.1016/J.Ygyno.2009.02.009 |
0.476 |
|
| 2009 |
Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 115: 1395-403. PMID 19195045 DOI: 10.1002/cncr.24152 |
0.334 |
|
| 2009 |
Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer. 115: 1028-35. PMID 19156927 DOI: 10.1002/Cncr.24084 |
0.369 |
|
| 2009 |
Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 112: 583-9. PMID 19110305 DOI: 10.1016/J.Ygyno.2008.11.013 |
0.381 |
|
| 2008 |
Krivak TC, Darcy KM, Tian C, Bookman MA, Baysal BA, Gallion HH, Ambrosone CB, DeLoia JA. Relationship between ERCC1 polymorphisms, disease progression, and survivalin GOG0182, a Gynecologic Oncology Group phase III trial of platinum-based chemotherapy in women with advanced stage epithelial ovarian or primary peritoneal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5540. PMID 27950477 DOI: 10.1200/Jco.2008.26.15_Suppl.5540 |
0.63 |
|
| 2008 |
Farley JH, Tian C, Rose GS, Brown CL, Risinger JI, Maxwell GL. Ethnicity and clinical outcome for advanced epithelial ovarian cancer patients treated by standard cisplatin/paclitaxel chemotherapy: A combined analysis of gynecologic oncology group clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5573. PMID 27950422 DOI: 10.1200/Jco.2008.26.15_Suppl.5573 |
0.538 |
|
| 2008 |
Maxwell GL, Tian C, Risinger JI, Hamilton CA, Barakat RR. Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy? Cancer. 113: 1431-7. PMID 18698590 DOI: 10.1002/Cncr.23717 |
0.489 |
|
| 2008 |
Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3598-606. PMID 18640939 DOI: 10.1200/Jco.2008.16.1323 |
0.608 |
|
| 2008 |
Wright JD, Tian C, Mutch DG, Herzog TJ, Nagao S, Fujiwara K, Powell MA. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 109: 353-8. PMID 18407341 DOI: 10.1016/J.Ygyno.2008.02.023 |
0.364 |
|
| 2008 |
Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 112: 2202-10. PMID 18348296 DOI: 10.1002/Cncr.23390 |
0.457 |
|
| 2008 |
Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 83-9. PMID 18025437 DOI: 10.1200/Jco.2007.13.1953 |
0.461 |
|
| 2007 |
Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3621-7. PMID 17704411 DOI: 10.1200/Jco.2006.10.2517 |
0.5 |
|
| 2007 |
Darcy KM, Tian C, Reed E. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Research. 67: 4474-81. PMID 17483363 DOI: 10.1158/0008-5472.Can-06-4076 |
0.414 |
|
| 2007 |
Monk BJ, Tian C, Rose PG, Lanciano R. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. Gynecologic Oncology. 105: 427-33. PMID 17275889 DOI: 10.1016/J.Ygyno.2006.12.027 |
0.442 |
|
| 2007 |
Modesitt SC, Tian C, Kryscio R, Thigpen JT, Randall ME, Gallion HH, Fleming GF. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecologic Oncology. 105: 59-65. PMID 17150247 DOI: 10.1016/j.ygyno.2006.10.045 |
0.308 |
|
| 2007 |
Moore DH, Tian C, Monk BJ, Long HJ, Omura G. Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: A multivariate analysis of three Gynecologic Oncology Group trials Journal of Clinical Oncology. 25: 5534-5534. DOI: 10.1200/JCO.2007.25.18_SUPPL.5534 |
0.303 |
|
| 2007 |
Krivak TC, Darcy KM, Tian C, Baysal BE, Armstrong DK, Gallion HH, Deloia JA. Relationship between polymorphisms in cordon 118 and C8092A in ERCC1 and clinical outcome in optimally-resected, stage III epithelial ovarian cancer treated with intraperitoneal or intravenous cisplatin and paclitaxel: A gynecologic oncology Journal of Clinical Oncology. 25: 21050-21050. DOI: 10.1200/Jco.2007.25.18_Suppl.21050 |
0.443 |
|
| 2007 |
ZHANG M, TIAN C, KAPP D, MONK B, HERZOG T, BELL J, CHAN J. Survival Outcome of Recurrent Early-Stage Ovarian Cancer Patients—What Factors are Important? Gynecologic Oncology. 107: 377-377. DOI: 10.1016/J.YGYNO.2007.08.047 |
0.387 |
|
| 2006 |
Ahn J, Ambrosone CB, Kanetsky PA, Tian C, Lehman TA, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Chang-Claude J. Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7063-70. PMID 17145829 DOI: 10.1158/1078-0432.Ccr-06-0039 |
0.461 |
|
| 2006 |
von Gruenigen VE, Tian C, Frasure H, Waggoner S, Keys H, Barakat RR. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. Cancer. 107: 2786-91. PMID 17096437 DOI: 10.1002/Cncr.22351 |
0.361 |
|
| 2006 |
Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, Fleming GF, Gallion HH, Brewster WR. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer. 107: 2197-205. PMID 17001661 DOI: 10.1002/cncr.22232 |
0.353 |
|
| 2006 |
Ambrosone CB, Tian C, Ahn J, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Chang-Claude J. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Research : Bcr. 8: R40. PMID 16848913 DOI: 10.1186/Bcr1526 |
0.47 |
|
| 2006 |
Hess LM, Tian C, Barakat R, Ozols R, Alberts D. Change in patient weight during platinum/paclitaxel-based chemotherapy for ovarian cancer: A Gynecologic Oncology Group study Journal of Clinical Oncology. 24: 5073-5073. DOI: 10.1200/Jco.2006.24.18_Suppl.5073 |
0.394 |
|
| 2004 |
Winter WE, Maxwell GL, Tian C, Sobel E, Rose GS, Thomas G, Carlson JW. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecologic Oncology. 94: 495-501. PMID 15297194 DOI: 10.1016/J.Ygyno.2004.04.008 |
0.443 |
|
| Show low-probability matches. |